74. Immunological aspects of treatment of Pompe disease
Priya S. Kishnani(Duke Medical Center), Y.T. Chen(Duke Medical Center), Suhrad G. Banugaria(Duke Medical Center), Stephanie DeArmey(Duke Medical Center), Dwight D. Koeberl(Duke Medical Center), Deeksha Bali(MRC Epidemiology Unit), Joanne Mackey(Duke Medical Center), Yoav H. Messinger(Children’s Minnesota - St. Paul Hospital), Sarah P. Young(Duke Medical Center), William J. Rhead(Children's Hospital of Wisconsin), Amy S. Rosenberg(Center for Drug Evaluation and Research), Nancy J. Mendelsohn
Cited by 0
Related Papers
An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge
|Genome biology|2014|432
Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders
|New England Journal of Medicine|2007|357
The genomic landscape of juvenile myelomonocytic leukemia
|Nature Genetics|2015|310
Glycogen Storage Disease Type III diagnosis and management guidelines
|Genetics in Medicine|2010|305
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
|Genetics in Medicine|2009|292